Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Prior Auth Coverage Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy 26328

    Prior Authorization Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for priority health Policy 26328 alerts

    Get alerted when Policy 26328 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists prior authorization requirements, exclusions, documentation, age and prescriber restrictions, coverage durations, and renewal criteria for numerous pharmacy and specialty drugs covered by Priority Medicare Dual Premier (HMO D-SNP). It affects prescribers and pharmacy adjudicators seeking authorization for the listed products.

    Policy Summary
    Payerpriority health
    PolicyPrior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with required diagnostic tests and documentation of prior therapy trials as specified for the requested product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Multipledrugs listed alphabetically with criteria
    1-2 yrstypical coverage duration for many agents
    Class-specificstep therapy frequently required
    Someprior documentation required
    20+products in this section

    Drug-specific Coverage Criteria

    Acthar

    Covered when ALL of the following are met:

    Acthar coverage and prerequisites: Documentation of prior therapies and responses demonstrating inadequate response, intolerance, or FDA‑labeled contraindication; therapeutic trial of a parenteral glucocorticoid AND Cortrophin for all covered indications except infantile spasms; quantity limited to FDA‑supported dosage; coverage duration: 6 weeks; reauthorization requires demonstrated clinical benefit; not covered for acute gouty arthritis, severe psoriasis, or atopic dermatitis.

    Prescriber and age restrictions per product entry

    Adempas

    Covered when ALL of the following are met:

    Adempas diagnostic requirements: FOR PAH: documentation of pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterization. FOR CTEPH: documentation of CTEPH (WHO Group 4) that is inoperable or persistent/recurrent after pulmonary endarterectomy.

    Coverage duration: two years

    Policy Summary
    Payerpriority health
    PolicyPrior Authorization Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with required diagnostic tests and documentation of prior therapy trials as specified for the requested product.
    SourceLink
    On This Page
    Drug-specific Coverage CriteriaCoding and Key Clinical ThresholdsPrior Authorization, Documentation, and Denial RisksPolicy BackgroundDefinitions and Clinical TermsInitial Therapy Criteria (Selected Products)Reauthorization / Continuation CriteriaStep Therapy RequirementsQuantity Limits and Dosing CapsSite of Care and Benefit Determination

    Amvuttra

    Covered per indication when the specified diagnostic and prior‑therapy conditions are met:

    HATTR‑PN initial coverage: Patient has a documented transthyretin (TTR) mutation AND baseline polyneuropathy disability (PND) score ≤ IIIb AND clinical signs/symptoms of neuropathy; Amvuttra must not be used with TTR stabilizers (e.g., tafamidis) or other TTR‑lowering agents; initial coverage age ≥18; duration one year; reauthorization requires documentation of positive clinical response compared to baseline.
    ATTR‑CM initial coverage: Trial with failure, intolerance, or contraindication to tafamidis AND NYHA class I–III heart failure with manifestations or prior HF hospitalization AND echocardiogram or CMR demonstrating cardiac involvement (increased LV wall thickness) AND diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (if radionuclide imaging used, require Grade 2 or 3 uptake); must not be used with TTR‑lowering agents; reauthorization requires documented clinical benefit.

    Initial coverage age ≥18; duration one year

    Anti-obesity GLP-1 agents

    Covered when ALL of the following are met (class‑level requirements and indication‑specific criteria):

    Prescriber attestations and exclusions: Prescriber attests patient will not use more than one anti‑obesity GLP‑1 concurrently; for patients with an eating disorder prescriber attests treatment optimized and safety confirmed; metabolic causes of obesity ruled out/treated; prescriber attests absence of contraindications including pregnancy, lactation, personal/family history of medullary thyroid cancer or MEN2; therapy is part of a comprehensive weight‑management plan (diet/exercise); documented failure of other clinically appropriate weight‑loss interventions; not concurrent with DPP‑4 inhibitors.

    Initial and reauthorization duration: 6 months

    Age and BMI prerequisites: Adolescents (12–17): BMI ≥95th percentile per CDC growth charts (or 85th–94th percentile with ≥1 comorbidity). Adults: BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with ≥1 qualifying comorbidity.

    Some agents have product‑specific age limits per labeling

    Renewal: Adults must demonstrate ≥5% weight loss from baseline for renewal; adolescents must show maintained or improved BMI percentile; established‑member first renewal prior to 1/1/2026 requires additional attestations per policy.

    Arikayce

    Covered when ALL of the following are met:

    Arikayce initial criteria: Submit sputum culture supporting Mycobacterium avium complex (MAC) pulmonary disease AND documentation of failure to achieve negative sputum cultures after ≥6 months of an appropriate multidrug background regimen; prescriber is or has consulted with an infectious disease specialist or pulmonologist; initial approval 6 months; reauthorization requires negative sputum culture within 30 days and evidence of clinical benefit.

    Nebulized/inhalation use not covered; IV/IM administration only for colistimethate is a separate entry

    Auvelity

    Covered when ALL of the following are met:

    Auvelity prerequisites: Trial and failure (inability to improve after ≥4 weeks) of an SSRI or SNRI AND one atypical antidepressant (e.g., bupropion or mirtazapine) prior to approval; submit documentation of prior therapies and responses; dosing per FDA label; coverage duration two years.

    Prescriber and other restrictions per product entry

    Austedo — TD initial coverage

    Initial TD requests covered when ANY of the following apply:

    Austedo TD initial conditions: 1) Using Austedo for TD not associated with dopamine‑receptor blocking agents; OR 2) TD associated with dopamine‑receptor blocking agents with symptoms persisting despite stopping or reducing the dopamine‑blocking agent; OR 3) stopping/reducing the dopamine‑blocking agent is not possible.

    Initial duration 1 year; reauthorization 2 years; must not be used with tetrabenazine or Ingrezza

    Benlysta — SLE and LN

    Covered when ALL of the following are met (separate nodes for SLE and lupus nephritis):

    Benlysta — SLE initial: SELENA‑SLEDAI score ≥6 AND either anti‑dsDNA >30 IU/mL or ANA >1:80; patient must be taking two of the following together for ≥12 weeks each: a steroid, an immunosuppressant, and/or hydroxychloroquine; prescriber must be a specialist or have consulted one; initial coverage 1 year; reauthorization 2 years with evidence of clinical improvement.
    Benlysta — Lupus nephritis initial: Confirmed SLE AND kidney biopsy confirming class 3, 4 and/or 5 disease; patient receiving standard therapy for LN (e.g., mycophenolate or azathioprine plus steroid); prescriber specialist required; reauthorization requires evidence of clinical improvement including improved or stable eGFR.

    Initial 1 year; reauth 2 years

    Cosentyx — indication-specific criteria

    Covered per indication when the specified prior‑therapy requirements are met:

    Psoriasis: Must try and fail one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before Cosentyx; prescriber specialist or consult required; dosing per FDA label; coverage duration 2 years.
    Ankylosing spondylitis / NRAS: Must try and fail one NSAID prior to Cosentyx; prescriber specialist or consult required; coverage duration 2 years; other indication‑specific prior therapy rules apply for ERA and hidradenitis suppurativa.

    Colistimethate — route and microbiology criteria

    Covered when ALL of the following are met:

    Colistimethate administration and microbiology: Drug must be administered IV or IM (nebulization/inhalation not covered) AND infection must be proven or strongly suspected to be caused by susceptible bacteria supported by culture and susceptibility testing OR local epidemiology and susceptibility patterns; prescriber is or has consulted with an infectious disease specialist; coverage duration one year.

    Nebulized/inhalation use not supported and is non‑covered

    Dalfampridine — MS walking aid

    Covered when ALL of the following are met:

    Dalfampridine safety and effectiveness: No history of seizure AND creatinine clearance > 50 mL/min AND baseline timed 25‑foot walk (T25FW) showing patient is ambulatory; reauthorization requires documentation of stability or improvement in walking speed; initial and reauthorization duration: 1 year.> 50 ml per min

    Diacomit (fenfluramine) — Dravet syndrome

    Covered when ALL of the following are met:

    Diacomit initial criteria: (1) Diagnosis of seizures associated with Dravet syndrome; AND (2) inadequate seizure control on current therapy (generalized tonic‑clonic or clonic seizures within past 28 days); AND (3) concomitant clobazam therapy; prescriber must be or consult a specialist; coverage duration two years.

    Dihydroergotamine mesylate nasal

    Covered when ALL of the following are documented:

    Dihydroergotamine nasal criteria: Trial and failure of one non‑oral triptan (e.g., sumatriptan nasal spray or injection) AND trial and failure of Nurtec ODT; failure is defined as inability to improve symptoms; coverage duration two years.

    Prescriber restrictions per product entry

    Dupixent (dupilumab) — multiple indications

    Initial coverage and reauthorization vary by indication — examples shown below:

    Asthma initial coverage (example): Oral corticosteroid‑dependent asthma OR eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation OR ≥300 cells/µL in past 12 months) AND trial and failure of one ICS/LABA in past 6 months (≥4 weeks); prescriber specialist or consult required; reauthorization requires documented clinical benefit compared to baseline; dosing per FDA label.>=150 cells/µL at initiation or >=300 cells/µL in past 12 months
    Eosinophilic esophagitis (EOE) initial: Diagnosis confirmed by esophageal biopsy with ≥15 eosinophils/HPF AND current weight ≥15 kg AND symptoms of esophageal dysfunction AND trial and failure of PPI or swallowed topical steroid for ≥2 months; reauthorization requires reduction in eosinophil count or symptoms.>=15 eos/HPF

    Prescriber is specialist or consulted

    Eltrombopag (Promacta) — ITP and other indications

    Criteria differ by indication; ITP example provided:

    Eltrombopag (Promacta) — ITP initial: Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding‑risk factors AND inadequate response or intolerance to steroids or IVIG AND inadequate response or intolerance to rituximab or splenectomy; must not be used in combination with other maintenance ITP drugs including other TPO‑RAs; reauthorization requires platelet <400 x10^9/L and evidence of response.<30,000/mcL or <50,000/mcL with bleeding

    Coverage duration per product entry

    Emgality (galcanezumab)

    Covered when ALL of the following are met (examples by indication):

    Migraine prevention initial: At least 4 migraine days per month; reauthorization requires documentation of decreased migraine days with treatment; dosing per FDA label.>=4 migraine days/month
    Cluster headache initial: Trial of verapamil with intolerance or inadequate response prior to Emgality; reauthorization requires decreased frequency or intensity of cluster headaches.

    Epclusa (sofosbuvir/velpatasvir)

    Covered when ALL of the following are met:

    Epclusa initial: Documentation of chronic hepatitis C infection and that use is consistent with current AASLD/IDSA guidance; for pellets (age 3–21) follow age restrictions; duration per AASLD/IDSA guidance.

    Evrysdi (risdiplam) — SMA

    Initial and reauthorization criteria:

    Evrysdi initial: Documentation of genetic test confirming SMA diagnosis; prescriber must be a neurologist or consult one; patient must not be receiving Spinraza or have previously received or plan to receive gene therapy (Zolgensma); initial approval 12 months; reauthorization 12 months and requires documentation of positive clinical response vs baseline.

    Evrysdi coverage criteria

    Coverage conditions (summary):

    Evrysdi initial/reauthorization and prescriber: Genetic test confirming SMA required; prescriber neurologist or consult; initial and reauthorization durations 12 months; concurrent Spinraza or planned/received gene therapy (Zolgensma) excludes coverage; reauthorization requires documentation of positive clinical response compared to baseline.

    Fasenra coverage criteria

    Covered when ALL of the following are met:

    Fasenra severe eosinophilic asthma initial: Blood eosinophils ≥150 cells/µL within 6 weeks prior to treatment OR ≥300 cells/µL in previous 12 months; trial and failure of 1 ICS/LABA inhaler in past 6 months (failure = inability to improve after ≥4 weeks); must not be used with other biologics; prescriber specialist or consult; dosing per FDA label; initial coverage 1 year; reauthorization requires documented clinical benefit vs baseline.eosinophils >=150 cells/µL or >=300 cells/µL
    Fasenra EGPA initial: Documentation patient has non‑severe EGPA (no life‑ or organ‑threatening manifestations); prescriber specialist; must not be used with other biologics; reauthorization requires documentation of clinical benefit; dosing per FDA label.

    Initial 1 year; reauth 2 years

    Growth hormone coverage criteria

    Covered when ALL of the following diagnostic criteria and documentation are provided:

    Pediatric growth hormone deficiency (GHD): Untreated growth‑velocity curve with ≥1 year of growth data showing velocity <10th percentile for bone age/gender; open growth plates; bone age at least 1 year behind chronological age (exceptions apply); documented GH deficiency via two stimulation tests <10 ng/mL OR stimulation <15 ng/mL plus low IGF‑1/IGFBP‑3; prescriber is endocrinologist/gastroenterologist/nephrologist; coverage duration typically one year.growth velocity <10th percentile; GH stimulation thresholds specified

    Increlex excluded for closed epiphyses

    Adult GHD: Confirm GHD by one of: suboptimal response on GH‑stimulation test, child‑onset GHD with confirmed persistent GHD, or documented pituitary/hypothalamic disease with ≥3 pituitary hormone deficiencies and low IGF‑1; reauthorization: above‑normal IGF‑1 requires provider attestation dose will be decreased.

    Adalimumab-class coverage criteria

    Class‑level biologic restrictions and prerequisites (applies to adalimumab class and similar biologics):

    General biologic criteria: Documentation of prior therapies and responses required; prescriber should be a specialist or have consulted a specialist; must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; dosing per FDA labeling or supported compendia for Part D; coverage durations commonly two years; for Crohn's/UC shortened‑interval dosing approvals require two of: symptoms, imaging showing active disease, fecal calprotectin >120, CRP ≥300, plus inadequate trough levels and initial response to therapy.fecal calprotectin >120; CRP >=300
    JIA exception: For juvenile idiopathic arthritis (JIA): must try and fail one other drug (e.g., methotrexate, sulfasalazine, NSAID) OR start adalimumab concurrently with methotrexate/sulfasalazine/leflunomide OR have aggressive disease per prescriber.

    HAE coverage criteria

    Covered when ALL of the following diagnostic and laboratory criteria are met:

    Haegarda maintenance therapy: Submission of C4, C1‑INH protein, and C1‑INH function laboratory results confirming HAE diagnosis; patient age ≥6; prescriber allergist/immunologist/hematologist or other HAE‑experienced specialist; initial coverage one year and reauthorization one year; not covered if used with ACE inhibitors or other preventative HAE therapies (e.g., Orladeyo, Takhyzro) or for acute attacks; reauthorization requires documentation of decreased attack frequency.age >=6
    Icatibant acute therapy: Submission of C4, C1‑INH protein, and C1‑INH function lab results confirming diagnosis; patient age ≥18; prescriber specialist; concurrent ACE inhibitor use is not covered; initial and reauthorization coverage 6 months; reauthorization requires documentation of prior approved syringes and favorable clinical response.age >=18

    Neurology/oncology product criteria

    Selected neurology/oncology product‑specific trial requirements (examples):

    Fintepla: Documentation of trial and failure (inadequate seizure control) with two of: clobazam, valproic acid, topiramate; coverage duration two years; indications per FDA label.
    Fanapt: Documentation of trial and failure with two of aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone, each used ≥28 days; coverage two years.>=28 days per agent
    Inrebic: Must have tried and failed Jakafi (intolerance or inability to improve condition) prior to coverage; coverage duration two years.

    Inlyta

    Inlyta coverage: Coverage duration two years; indications: all medically‑accepted indications per product entry.

    Inrebic

    Inrebic: Must have tried and failed Jakafi (intolerance or inability to improve condition) prior to coverage; coverage duration two years; indications per FDA labeling.

    IVIG products

    IVIG products requirements: Provide current weight and requested dose; dosing must follow FDA labeling or have documentation supporting accepted standards; adjust dose if BMI ≥30 or actual body weight ≥20% above ideal; medical records supporting diagnosis and dose required; for myasthenia gravis only acute myasthenic crisis with decompensation is covered; chronic/routine use in stable MG not covered; coverage duration one year.

    Administration info reviewed to determine Medicare Part B vs Part D benefit

    Kalydeco

    Kalydeco (ivacaftor) coverage: Laboratory confirmation of an ivacaftor‑responsive CFTR mutation required; coverage duration two years; indications per FDA labeling.

    Kerendia

    Kerendia (HF and CKD) initial: For HF (LVEF ≥40%): NYHA class II–IV AND documented EF ≥40% within prior 12 months AND pre‑treatment eGFR ≥25 mL/min/1.73m2 AND prescribed by/consult with cardiologist AND patient on at least two standard HF medications from different classes. For CKD with T2DM: must try an SGLT2 inhibitor or GLP‑1 RA initially and be on maximally tolerated ACEI or ARB; eGFR ≥25 mL/min/1.73m2. Coverage duration two years.eGFR >=25

    Livtencity

    Livtencity coverage: Baseline CMV DNA level confirming diagnosis required; must have documented trial and failure with ganciclovir, valganciclovir, cidofovir or foscarnet; must not be used concomitantly with other CMV antivirals; dosing per FDA labeling; coverage duration 8 weeks; reauthorization requires documentation of response (e.g., CMV DNA level).

    Lybalvi

    Lybalvi coverage conditions: Patient ≥18 years AND not currently using opioids or undergoing acute opioid withdrawal; must have trial and failure of olanzapine AND another generic atypical antipsychotic (e.g., aripiprazole or lurasidone) where failure is defined as clinical response accompanied by ≥7% weight gain from baseline; documentation of diagnosis, baseline and current weight, and prior therapies required; coverage duration one year.>=7% weight gain compared to baseline

    Not covered in patients using opioids

    Nexletol / Nexlizet

    Covered when ANY of the following are met (summarized initial‑therapy logic):

    Nexletol / Nexlizet initial conditions: Patient has tried one high‑intensity statin (or maximally tolerated statin if high‑intensity not tolerated) plus ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL OR tried ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL and is statin‑intolerant (defined as trial of ≥2 statins with statin‑related symptoms on both); must submit most recent LDL‑C and documentation of prior therapies and responses; must not be used concomitantly with PCSK9 inhibitors (e.g., Repatha) or Juxtapid; coverage duration two years.LDL-C >= 70 mg/dL

    Statin intolerance defined in policy

    Nexlizet — Initial Therapy

    Nexlizet — Covered when ALL of the following are met:

    Nexlizet initial coverage criteria: 1) Trial of a high‑intensity statin (or maximally tolerated statin) plus ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL OR trial of ezetimibe ≥4 weeks with LDL‑C ≥70 mg/dL in statin‑intolerant patients (statin intolerance = tried ≥2 statins with statin‑related symptoms). 2) Must not be used concomitantly with PCSK9 inhibitors or Juxtapid. 3) Submit most recent LDL‑C and documentation of prior therapies and responses. Coverage duration two years.LDL-C >= 70 mg/dL

    Antifibrotic agents — IPF and progressive fibrosing ILD

    Antifibrotic agents are covered when ALL of the following are documented:

    Antifibrotic initial criteria: 1) HRCT confirming diagnosis; 2) prescriber is or has consulted with a pulmonologist; 3) for IPF: rule out other known causes of interstitial lung disease and presence of UIP pattern on HRCT if no surgical lung biopsy; 4) for chronic fibrosing ILD with progressive phenotype: FVC decline ≥10% OR ≥5% plus either worsening respiratory symptoms OR worsening fibrosis on imaging; 5) dosing must follow FDA labeling. Initial coverage typically one year; reauthorization requires documentation of improvement or stability as specified.FVC decline >=10% OR >=5% plus worsening symptoms or imaging fibrosis

    Nurtec — Indication-specific criteria

    Nurtec coverage varies by indication:

    Nurtec initial — prevention vs acute: Prevention: at least 4 and <15 migraine days per month. Acute: trial and failure of one generic triptan unless contraindicated. Reauthorization for prevention requires continued meeting of prevention thresholds and documentation of decreased migraine days per month with Nurtec. Must not be used with other CGRP antagonist therapy. Initial and reauthorization duration: 1 year.4-14 migraine days/month

    Oxervate — Neurotrophic keratitis

    Covered when ALL of the following are met:

    Oxervate criteria: Documentation confirming Stage 2 (persistent epithelial defect) or Stage 3 (corneal ulcer) neurotrophic keratitis (e.g., slit‑lamp exam); prescribed by or in consultation with an ophthalmologist; dosing per FDA label; total treatment limited to 8 weeks lifetime; coverage duration 8 weeks.8 weeks lifetime max

    Reauthorization beyond lifetime limit not permitted

    Otezla — Psoriasis and Behcet's disease

    Covered when ALL of the following are met (psoriasis and Behcet's examples):

    Otezla — moderate to severe psoriasis: Must try and fail one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) prior to Otezla for moderate‑severe psoriasis (step not required for mild psoriasis); documentation of prior therapies and responses required; dosing per FDA label; coverage duration 2 years.
    Otezla — Behcet's oral ulcers: For oral ulcers associated with Behcet's: must try and fail one other systemic therapy (e.g., colchicine, thalidomide, interferon alpha, TNF inhibitors); documentation of prior therapies and response required.

    Radicava — Initial and Reauthorization Criteria

    Covered when ALL of the following are met for initial requests; reauthorization requires evidence of clinical benefit:

    Radicava initial: (1) Diagnosis of definite or probable ALS per revised El Escorial/Arlie House criteria; (2) diagnosis ≤2 years (provide date of diagnosis); (3) baseline ALSFRS‑R score with at least 2 points on each of 12 items (minimum total 24); (4) % predicted FVC ≥80%; initial volume limits apply (70 mL first 28 days, then 50 mL every 28 days).minimum ALSFRS-R 24; FVC >=80%

    Reauthorization: documentation that Radicava is slowing progression vs baseline

    Radicava reauthorization: Documentation that Radicava is slowing progression as shown by improved or stable ALSFRS‑R or other supporting clinical documentation.

    Promacta (eltrombopag) — ITP Initial and Reauthorization Criteria

    Covered when ALL/ANY of the following are met (ITP example and reauth):

    Promacta platelet threshold: Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding‑risk factors (history of bleeding, anticoagulation, etc.).<30,000/mcL or <50,000/mcL with bleeding
    Promacta prior therapy: Inadequate response or intolerance to steroids or IVIG AND inadequate response or intolerance to rituximab or splenectomy prior to initiation. Not to be used to normalize platelet counts. Reauthorization requires current platelet count <400 x10^9/L and evidence of response.<400 x10^9/L for reauth

    Prolastin-C (alpha1-proteinase inhibitor) Coverage Criteria

    Covered when ALL of the following are met:

    Prolastin‑C physiologic and lab criteria: FEV1 less than 80% predicted AND serum alpha‑1 antitrypsin (AAT) level <11 micromoles per liter (or 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry). Provide pulmonary function and AAT testing documentation; dosing per labeling and HRCT where applicable.AAT <11 micromoles/L; FEV1 <80% pred

    Sodium Oxybate — Narcolepsy Coverage Criteria

    Covered when ALL of the following are met for narcolepsy with excessive daytime sleepiness in adults:

    Sodium oxybate diagnostic confirmation: Polysomnography and MSLT confirming narcolepsy; prescriber must be a sleep specialist or neurologist; documentation of prior therapy trials (trial and failure of amphetamine salts/dextroamphetamine/methylphenidate AND modafinil or armodafinil) required prior to initiation; reauthorization requires documentation of decreased excessive daytime sleepiness or decreased cataplexy episodes; initial coverage two years.

    Must not be receiving sedative hypnotics or have succinic semialdehyde dehydrogenase deficiency

    Biologics / JAKi / Targeted Therapies — Class-level Restrictions

    Class‑level restrictions for biologics/JAKi/targeted therapies:

    Combination restrictions: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors where specified; documentation of prior therapies and responses must be provided; prescriber is a specialist or has consulted a specialist. For psoriasis, must try and fail one traditional non‑biologic immunomodulator before biologic initiation.

    Coverage duration commonly two years; dosing per FDA label or compendia

    Ustekinumab (and similar biologics) coverage conditions

    Covered when ALL of the following are met:

    Ustekinumab and similar biologics conditions: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; documentation of prior therapies and responses required; prescriber is a specialist or has consulted one; coverage duration two years; dosing must follow FDA label or be supported in compendia; for psoriasis must try and fail one traditional non‑biologic immunomodulator.

    Sodium oxybate coverage conditions (narcolepsy)

    Covered when ALL of the following are met:

    Sodium oxybate narcolepsy conditions: Documented MSLT and polysomnography confirming narcolepsy; prior trial and failure of stimulants (amphetamine salts/dextroamphetamine/methylphenidate) AND either modafinil or armodafinil; prescriber sleep specialist or neurologist; patient must not be receiving sedative hypnotics or have succinic semialdehyde dehydrogenase deficiency; initial coverage two years; reauthorization requires documentation of decreased excessive daytime sleepiness or decreased cataplexy episodes.

    Tavneos coverage conditions

    Covered when ALL of the following are met:

    Tavneos initial criteria: Documentation to support diagnosis of the condition; patient age ≥18; prescriber is or has consulted with a specialist; used as add‑on to standard therapy (cyclophosphamide, rituximab, steroids) and patient not currently on dialysis; initial coverage 6 months; reauthorization requires BVAS reduction and steroid dose documentation; reauth 12 months.

    Tolvaptan coverage indicators and dosing limits

    Covered when ALL of the following are met (by indication):

    Tolvaptan indications: Indication either hyponatremia or ADPKD consistent with FDA‑approved uses.
    Hyponatremia documentation: Documentation confirming hypervolemic or euvolemic hyponatremia with serum sodium <125 mEq/L OR symptomatic nonresponsive hyponatremia; dosing up to 60 mg/day per FDA labeling for hyponatremia; coverage hyponatremia 30 days.serum sodium <125 mEq/L
    ADPKD documentation and dosing: For ADPKD: patient at risk of rapidly progressing disease; tolvaptan dosing up to 120 mg/day per FDA labeling; coverage duration two years for ADPKD.

    Teriparatide/Tymlos coverage conditions (osteoporosis)

    Covered when ALL of the following are met (teriparatide/Tymlos — osteoporosis):

    Prior trial or very high fracture risk: Documentation of either: (1) trial and failure, intolerance, or contraindication to oral bisphosphonates (alendronate, risedronate, or ibandronate) AND zoledronic acid, OR (2) very high fracture risk defined as T‑score ≤‑3.0 OR T‑score ≤‑2.5 with a fragility fracture OR history of severe/multiple fragility fractures regardless of T‑score.T-score ≤ -3.0 (or ≤ -2.5 with fragility fracture)

    Prescriber must be an endocrinologist; coverage duration two years

    Prescriber requirement: Must be prescribed by an endocrinologist.

    Tyenne coverage conditions

    Covered when ALL of the following are met:

    Tyenne coverage conditions: Must not be used in combination with other biologic drugs, Otezla, JAK inhibitors, or Ofev; documentation of prior therapies and responses required; prescriber specialist or consult required; for SSc‑ILD HRCT confirmation required; for RA and JIA must have trial and failure of two of preferred adalimumab product, Rinvoq, Xeljanz/XR, or Enbrel; coverage duration two years; dosing per FDA label.

    Somavert coverage conditions

    Somavert coverage: Coverage duration one year; indications per FDA labeling and medical necessity documentation as required in product entry.

    Voydeya Initial Coverage

    Voydeya initial coverage is allowed when ALL of the following are met:

    Voydeya initial coverage: Diagnosis of PNH confirmed by flow cytometry; patient is actively receiving ravulizumab or eculizumab; symptomatic extravascular hemolysis defined as fatigue or dyspnea AND (Hgb <9.5 g/dL OR absolute reticulocyte count >120 x10^9/L); patient age ≥18; prescriber specialty per product; initial coverage one year; reauthorization requires documentation of improvement in EVH symptoms and sustained hematologic benefit vs baseline.Hgb <9.5 g/dL

    Vyndamax ATTR-CM Criteria

    Vyndamax covered when ALL of the following are met for ATTR‑CM:

    Vyndamax initial coverage: NYHA class I–III heart failure; ECHO or CMR demonstrating cardiac involvement (increased LV wall thickness); diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc‑PYP/DPD/HMDP); if confirmed by radionuclide imaging, documentation of Grade 2 or 3 cardiac uptake required; patient age ≥18; not approved for primary (light‑chain) amyloidosis; initial coverage one year; reauthorization requires documentation of clinical benefit vs baseline.

    Xolair Asthma Criteria

    Xolair initial asthma coverage requires ALL of the following:

    Xolair asthma initial: Baseline IgE ≥30 IU/mL (baseline defined as before therapies that lower IgE) AND baseline positive skin test or in‑vitro reactivity to a perennial aeroallergen AND patient's current weight provided AND trial and failure of one ICS/LABA inhaler in past 6 months (failure defined as inability to improve after ≥4 weeks); prescriber specialist or consult required; initial coverage one year; reauthorization requires documentation of clinical benefit and current weight.IgE >=30 IU/mL

    Xifaxan Coverage Limits

    Xifaxan coverage rules (selected limits):

    Xifaxan IBS‑D: Coverage limited to no more than three 14‑day treatment courses for IBS‑D; coverage for small intestinal bacterial overgrowth (SIBO) is not provided. For travelers' diarrhea: trial and failure with azithromycin required. For hepatic encephalopathy: trial and failure with lactulose required.max 3 courses

    Vowst Criteria

    Vowst is covered when ALL of the following are met:

    Vowst initial: Documentation of at least 2 recurrent CDI episodes (3+ total) after failure of appropriate antibiotic treatments; patient age ≥18; limited to one treatment course (12 capsules over 3 days); coverage duration one year.one treatment course (12 capsules over 3 days)

    Xolair — Initial coverage for IgE-mediated food allergy

    Covered when ALL of the following are met (food allergy initial coverage):

    Xolair food allergy initial: Diagnosis of IgE‑mediated food allergy confirmed by BOTH a positive in‑vitro specific IgE to the specified foods AND a positive skin prick test to the specified foods; clinical history of a significant allergic reaction to the specified foods; baseline IgE ≥30 IU/mL (baseline defined as before IgE‑lowering therapy); Xolair to be used with a food allergen‑avoidant diet; patient's current weight provided; patient age ≥1 year; prescriber and documentation per product entry.IgE >= 30 IU/mL

    Reauthorization requires continued avoidance diet, current weight, baseline IgE and documentation of clinical benefit

    Xolair — Reauthorization for food allergy

    Reauthorization requires ALL of the following:

    Xolair food allergy reauthorization: Continued use of Xolair in conjunction with a food allergen‑avoidant diet; patient's current weight and baseline IgE level provided; documentation of clinical benefit compared to baseline as applicable.

    Xolair — Initial coverage for chronic urticaria (CU)

    Covered when ALL of the following are met (chronic urticaria initial coverage):

    Xolair CU initial coverage: Confirmed diagnosis of chronic urticaria (urticaria >6 weeks) AND trial and failure of one H1 antihistamine (failure = inability to improve symptoms); prescriber documentation and prior therapy documentation required; reauthorization requires documentation of clinical benefit vs baseline.>6 weeks

    Xolair — Reauthorization for chronic urticaria

    Reauthorization requires:

    Xolair CU reauthorization: Documentation of clinical benefit with Xolair compared to baseline (e.g., improved symptoms); current weight and other required labs per product entry must be provided.

    Xolair — Initial coverage for nasal polyps

    Covered when ALL of the following are met (nasal polyps initial coverage):

    Xolair nasal polyps initial: Baseline IgE ≥30 IU/mL; patient's current weight provided; trial and failure of an intranasal steroid (failure = inability to adequately improve symptoms); patient will continue intranasal steroid along with Xolair; prescriber specialist or consult; initial coverage one year; reauthorization requires documentation of clinical benefit and current weight/baseline IgE.IgE >=30 IU/mL

    Xolair — Reauthorization for nasal polyps

    Reauthorization requires ALL of the following:

    Xolair nasal polyps reauthorization: Continued intranasal steroid use with Xolair; documentation of clinical benefit vs baseline (decreased exacerbations, symptom improvement, decreased oral steroid use); patient's current weight and baseline IgE must be provided.

    Yorvipath — Coverage for hypoparathyroidism

    Initial coverage is allowed when ALL of the following are met:

    Yorvipath initial coverage: Confirmed diagnosis of chronic hypoparathyroidism for ≥6 months with labs drawn together (PTH, calcium, magnesium, phosphate) AND provider attestation condition not adequately controlled on calcium and vitamin D therapy AND patient age ≥18 AND prescribed by or in consultation with an endocrinologist; reauthorization requires documented improved serum calcium.>=6 months

    Coding and Key Clinical Thresholds

    Listed products (examples)NDC|product
    Vitrakvi Oral Capsule 100 MG, 25 MGproduct listed
    Vitrakvi Oral Solutionproduct listed
    Vizimproproduct listed
    Vonjoproduct listed
    Listed products (examples)NDC|product
    Xifaxan Oral Tablet 200 MG, 550 MGproduct listed
    Listed products (examples)NDC|product
    Xolairproduct listed
    Formulary entries (no billing/CPT/ICD codes present)mixed
    No codes listed
    inv-104: Creatinine clearance
    Creatinine clearance requirement> 50 mL/min (required; patients with creatinine clearance ≤50 mL/min are ineligible)
    Safety exclusionNo history of seizure (contraindication)
    Baseline functional documentationBaseline timed 25-foot walk (T25FW) with patient currently ambulatory
    inv-105: SELENA-SLEDAI score
    SELENA-SLEDAI threshold>= 6 (required for Benlysta SLE initial requests)
    Concurrent baseline therapyPatient must be taking two of: steroid, immunosuppressant, and/or hydroxychloroquine for ≥12 weeks each
    Prescriber requirementPrescriber must be a specialist or have consulted a specialist
    inv-106: Anti-dsDNA or ANA
    Anti-dsDNA / ANA serologyanti-dsDNA > 30 IU/mL OR ANA > 1:80 (required for Benlysta SLE initial requests)
    Role in eligibilityOne of these serologic criteria plus SELENA-SLEDAI ≥6 required for initiation
    Documentation noteSerologic results required as part of prior authorization submission
    inv-107: eosinophil count threshold for asthma biologic
    Eosinophil threshold (initiation)>= 150 cells/µL at therapy initiation (or >=300 cells/µL in past 12 months) for eosinophilic asthma phenotype
    Prior therapy requirementTrial and failure of one ICS/LABA in past 6 months (failure = inability to improve after ≥4 weeks)
    Prescriber requirementPrescriber must be a specialist or have consulted with a specialist
    inv-108: esophageal biopsy threshold for EOE
    Esophageal biopsy threshold>= 15 eosinophils per high power field (HPF) to confirm EoE
    Symptom and weight requirementsSymptoms of esophageal dysfunction AND current weight ≥15 kg required for pediatric/adolescent dosing contexts
    Prior therapy requirementTrial and failure of PPI or swallowed topical steroid for ≥2 months required
    inv-109: platelet count threshold for ITP initial requests (eltrombopag)
    Initial platelet threshold (ITP)Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors (e.g., anticoagulation, peptic ulcer, falls)
    Prior therapy requiredInadequate response or intolerance to steroids or IVIG AND to rituximab or splenectomy
    Combination restrictionNot to be used in combination with other maintenance ITP drugs including other TPO-RAs
    inv-110: IVIG weight adjustment
    Weight-adjusted dosing ruleAdjust IVIG dose if BMI ≥30 OR actual body weight is ≥20% above ideal body weight
    Documentation requiredProvide current weight and requested dose to determine Medicare Part B vs Part D benefit
    Dosing standardDosing should follow FDA labeling or accepted standards/compendia
    inv-111: Lybalvi weight-gain failure definition
    Weight-gain failure definition≥7% weight gain from baseline (while on olanzapine) defines failure for Lybalvi consideration
    Prior trials requiredMust have tried and failed olanzapine and another generic atypical antipsychotic (e.g., aripiprazole or lurasidone)
    Opioid exclusionNot covered for patients currently using opioids or undergoing acute opioid withdrawal
    inv-112: Nexletol/Nexlizet LDL-C threshold
    LDL-C threshold for Nexletol/NexlizetLDL-C ≥ 70 mg/dL after prior therapies (high-intensity statin + ezetimibe or ezetimibe alone if statin-intolerant)
    Required prior therapyTrial of a high-intensity statin plus ezetimibe for ≥4 weeks OR ezetimibe ≥4 weeks if statin-intolerant (statin intolerance = tried ≥2 statins with symptoms)
    Concurrency exclusionMust not be used concomitantly with PCSK9 inhibitors (e.g., Repatha) or Juxtapid
    inv-113: Migraine days (Nurtec prevention)
    Migraine days threshold (prevention)At least 4 and fewer than 15 migraine headache days per month for Nurtec prevention
    Acute indication requirementFor acute use: trial and failure of one generic triptan unless contraindicated
    Reauthorization evidenceDocumentation of decreased migraine days per month required for reauthorization
    inv-114: LDL-C threshold (Nexlizet)
    Nexlizet LDL-C thresholdLDL-C >= 70 mg/dL (required for Nexlizet initial approval criteria)
    Laboratory submissionMost recent LDL-C level must be submitted with prior therapy documentation
    Statin-intolerance definitionStatin intolerance defined as trying at least two different statins with statin-related symptoms on both agents
    inv-115: FVC decline threshold (nintedanib/Ofev re: progressive phenotype)
    FVC decline thresholdFVC decline ≥10% OR ≥5% plus either worsening respiratory symptoms OR worsening fibrosis on imaging (defines progressive phenotype)
    HRCT requirementHRCT confirming diagnosis is required for antifibrotic agents (nintedanib/Ofev) for all indications
    Prescriber requirementPrescriber must be or have consulted with a pulmonologist/specialist
    inv-116: Radicava initial volume limits
    Initial volume limits (Radicava ORS)Limited to 70 mL during the first 28 days and 50 mL every 28 days thereafter
    Initial diagnostic criteriaALS diagnosis per revised El Escorial criteria; diagnosis ≤2 years; baseline ALSFRS-R ≥24; %FVC ≥80%
    Reauthorization evidenceDocumentation that Radicava is slowing progression (improved or stable ALSFRS-R) required for reauth
    inv-117: Prolastin-C AAT level threshold
    Serum AAT thresholdSerum AAT <11 micromoles per liter (or 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry)
    Pulmonary function requirementFEV1 less than 80% predicted (required alongside low serum AAT)
    Diagnostic documentationProvide HRCT confirmation for some indications as specified
    inv-118: Radicava ALSFRS-R baseline requirement
    ALSFRS-R baseline requirementMinimum ALSFRS-R total score of 24 (i.e., at least 2 points on each of 12 items) prior to Radicava initiation
    Diagnosis timingDiagnosis of definite or probable ALS per revised El Escorial criteria and duration ≤2 years
    Respiratory functionPercent-predicted FVC ≥80% required at baseline
    inv-119: Sodium oxybate reauthorization evidence
    Reauthorization evidenceDocumentation of decreased excessive daytime sleepiness or decreased cataplexy episodes required for sodium oxybate reauthorization
    Diagnostic confirmationMSLT and polysomnography confirming narcolepsy required for initial approval
    Prior therapy requirementMust try and fail stimulant (amphetamine/dextroamphetamine/methylphenidate) AND modafinil or armodafinil prior to sodium oxybate
    inv-120: Serum sodium for hyponatremia
    Serum sodium threshold (hyponatremia)Serum sodium <125 mEq/L for hyponatremia indication (documentation required)
    Indication-specific dosingDose limited to up to 60 mg/day for hyponatremia and up to 120 mg/day for ADPKD per FDA labeling
    Diagnostic requirementDocument hypervolemic or euvolemic hyponatremia (e.g., SIADH, heart failure) and nonresponse to fluid restriction where applicable
    inv-121: Very high fracture risk T-score threshold
    Very high fracture risk T-scoreT-score ≤ -3.0 OR T-score ≤ -2.5 with a fragility fracture (defines very high fracture risk)
    Prior therapy alternativeOr documentation of trial/failure or intolerance to bisphosphonates (alendronate, risedronate, ibandronate) plus zoledronic acid
    Prescriber requirementMust be prescribed by an endocrinologist
    inv-122: Baseline IgE
    Baseline IgE requirement>= 30 IU/mL (baseline defined as before treatment with Xolair or another IgE-lowering therapy)
    Baseline definitionMeasured before initiation of therapy that lowers IgE (baseline IgE)
    Use casesRequired for Xolair asthma, nasal polyps, and food allergy initial coverage per indication-specific rules
    inv-123: Hemoglobin threshold for Voydeya EVH
    Hemoglobin threshold for EVH (Voydeya)Hemoglobin < 9.5 g/dL used as part of symptomatic extravascular hemolysis (EVH) criteria
    Additional EVH markerAbsolute reticulocyte count >120 x10^9/L can also indicate EVH when present with symptoms
    Diagnostic confirmationPNH diagnosis must be confirmed by flow cytometry and patient actively receiving ravulizumab or eculizumab
    inv-124: Baseline IgE threshold
    Baseline IgE threshold (Xolair)>= 30 IU/mL (baseline defined as before therapy that lowers IgE)
    Indication applicationsApplies to food allergy, nasal polyps, and asthma initial coverage rules
    Documentation noteBaseline IgE must be submitted for initial authorization and reauthorization as specified
    inv-125: Minimum age for Xolair in food allergy
    Minimum age for Xolair (food allergy)>= 1 year (patient must be at least 1 year of age for food-allergy indication)
    Required testingBoth positive in vitro specific IgE and positive skin prick test to the specified foods required
    Additional requirementsClinical history of significant allergic reaction and use with food allergen-avoidant diet; patient's current weight required

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required

    Prior authorization is required for the specialty and pharmacy products listed in this policy; an alphabetical index of covered drugs appears after the criteria listings. Providers must submit required clinical documentation per the product-specific criteria to support approval.

    Prior Authorization

    Weight management PA duration

    Initial and reauthorization approvals for anti‑obesity (weight‑management) GLP‑1 agents are limited to 6 months; renewal requires meeting the documented weight‑loss renewal criteria (e.g., ≥5% weight loss in adults).

    Prior Authorization

    Austedo prior authorization

    Austedo (deutetrabenazine) requires prior authorization: initial approval for TD or Huntington’s chorea is one year and reauthorization two years; provider must attest symptoms have improved or stabilized for reauthorization and Austedo must not be used with tetrabenazine or Ingrezza.

    • Initial duration: 1 year; reauthorization: 2 years
    • Provider must attest symptoms improved or stabilized for reauth
    • Combination exclusion: do not use with tetrabenazine or Ingrezza
    Prior Authorization

    Avmapki Fakzynja prior authorization

    Avmapki Fakzynja Co‑Pack requires prior authorization with a one‑year coverage duration; providers must submit documentation of prior therapies and responses and meet any step‑therapy prerequisites.

    • Coverage duration: one year
    • Document prior therapies and responses
    • Step‑therapy prerequisite applies
    Prior Authorization

    Benlysta prior authorization

    Benlysta (belimumab) requires prior authorization: initial approvals are one year and reauthorization two years; prescriber must be a specialist or consult one and initial requests must meet specified clinical and serologic criteria (SELENA‑SLEDAI ≥6 and antibody criteria or biopsy‑confirmed lupus nephritis).

    • Initial: 1 year; reauthorization: 2 years
    • Prescriber must be specialist or consulted
    • SLE initial: SELENA‑SLEDAI ≥6 AND anti‑dsDNA >30 IU/ml or ANA >1:80
    • LN initial: kidney biopsy confirming class 3, 4 and/or 5 disease
    Prior Authorization

    Cosentyx prior authorization

    Cosentyx requires prior authorization for two years; prescriber must be a specialist or consult one and documentation of prior therapies and responses is required (condition‑specific prior trials such as NSAID for AS or methotrexate for psoriasis).

    • Coverage duration: 2 years
    • Prescriber specialist or consultation required
    • Document prior trials/responses (e.g., NSAID for AS; methotrexate for psoriasis)
    Prior Authorization

    Diacomit: Dravet syndrome prior auth

    Diacomit (fenfluramine) prior authorization for Dravet syndrome requires documentation that the patient has seizures associated with Dravet syndrome, is not controlled on current therapy (seizures within prior 28 days), and is taking concomitant clobazam; prescriber must be or consult a specialist.

    • Diagnosis of seizures associated with Dravet syndrome
    • Uncontrolled on current therapy (generalized tonic‑clonic or clonic seizures within past 28 days)
    • Concomitant clobazam therapy required
    • Prescriber specialist or consultation required
    Prior Authorization

    Dupixent prior auth

    Dupixent initial and reauthorization requests require disease‑specific documentation (for example, eosinophil counts for eosinophilic asthma or biopsy confirmation for EoE), prior therapy failures, and evidence of clinical benefit for reauthorization; prescriber should be a specialist or have consulted one.

    • Provide required diagnostic tests (e.g., eosinophil counts; esophageal biopsy ≥15 eos/HPF for EoE)
    • Document prior therapy failures per indication
    • Reauthorization requires documentation of clinical benefit
    Prior Authorization

    Evrysdi prior authorization

    Evrysdi (risdiplam) requires prior authorization: initial and reauthorization durations are 12 months; prescriber must be a neurologist or consult one, submit genetic test confirming SMA diagnosis, and reauthorization must document positive clinical response versus baseline; concurrent Spinraza or prior/planned gene therapy (Zolgensma) precludes concurrent Evrysdi.

    • Initial: 12 months; reauth: 12 months
    • Submit genetic test confirming SMA
    • Prescriber neurologist or consult required
    • Cannot be used concurrently with Spinraza or prior/planned Zolgensma
    • Reauthorization: document positive clinical response vs baseline
    Prior Authorization

    Fasenra prior authorization

    Fasenra requires prior authorization with initial coverage of one year and reauthorization of two years; dosing must follow FDA labeling, prescriber should be a specialist or consulted, and initial requests must include required blood eosinophil counts and trial/failure of an ICS/LABA.

    • Initial: 1 year; reauth: 2 years
    • Eosinophil requirement: ≥150 cells/µL within 6 weeks OR ≥300 cells/µL in prior 12 months
    • Document trial and failure of 1 ICS/LABA in past 6 months
    • Must not be used with other biologic drugs
    Prior Authorization

    Growth hormone prior authorization

    Growth hormone therapies (e.g., Norditropin, Omnitrope, Increlex) require prior authorization—typically one‑year approvals—with extensive diagnostic documentation (growth velocity curves, stimulation testing, IGF‑1 levels, open growth plates for pediatrics) and specialist prescribing.

    • Provide untreated growth velocity curve (≥1 year) and GH stimulation testing as specified
    • Prescriber must be endocrinologist/gastroenterologist/nephrologist
    • Coverage duration commonly one year
    Prior Authorization

    Biologic prior authorization

    Biologic agents (e.g., adalimumab products) require prior authorization: documentation of prior therapies and responses, specialist prescriber or consultation, dosing per FDA label (or compendia for Part D), and common two‑year coverage durations; many biologics also have combination therapy exclusions.

    • Document prior therapy trials and responses
    • Prescriber specialist or consult required
    • Dosing must follow FDA label or supported compendia
    • Coverage commonly 2 years
    • Combination exclusions with other biologics, Otezla, or JAKis
    Prior Authorization

    Product-specific prior authorization

    Coverage durations and prior authorization requirements vary by product; providers must follow the product‑specific prior authorization instructions and submit required documentation per the product entry.

    • Confirm product‑specific initial duration (commonly 1–2 years)
    • Submit documentation required in the product entry
    Prior Authorization

    IVIG prior authorization

    IVIG prior authorization requires submission of current weight, requested dose, supporting medical records for the diagnosis and dosing, and dosing consistent with FDA labeling or accepted standards (with weight‑adjustment rules for BMI ≥30 or actual weight ≥20% over ideal); IVIG for chronic/routine use in stable myasthenia gravis is not covered except for acute myasthenic crisis with decompensation.

    • Provide current weight and requested dose
    • Dose per FDA label or accepted standards; adjust dosing for BMI ≥30 or actual weight ≥20% over ideal
    • Document diagnosis and indication; chronic routine IVIG for stable MG not covered
    Prior Authorization

    Nexlizet prior authorization

    Nexlizet requires prior authorization with submission of the most recent LDL‑C and documentation of prior therapies and responses; patient must have tried a high‑intensity statin plus ezetimibe (or maximally tolerated statin plus ezetimibe) for at least 4 weeks with LDL‑C ≥70 mg/dL, or ezetimibe ≥4 weeks if statin‑intolerant; concurrent use with PCSK9 inhibitors is excluded. Coverage duration: two years.

    • Submit most recent LDL‑C
    • Document trial of high‑intensity statin + ezetimibe ≥4 weeks (LDL‑C ≥70 mg/dL) OR ezetimibe ≥4 weeks if statin‑intolerant
    • Statin intolerance = tried ≥2 statins with symptoms on both
    • Do not use with PCSK9 inhibitors (concurrency exclusion)
    • Coverage duration: 2 years
    Prior Authorization

    Nurtec prior authorization

    Nurtec requires prior authorization for prevention and acute indications; prevention requires 4–14 migraine days/month and reauthorization documents decreased migraine days; combination use with other CGRP antagonists is excluded. Initial and reauth durations are 1 year.

    • Prevention: 4–14 migraine days/month
    • Acute: trial/failure of one generic triptan unless contraindicated
    • Must not be used with other CGRP antagonist therapy
    • Initial and reauth: 1 year
    Prior Authorization

    Antifibrotic agents prior authorization

    Antifibrotic agents (nintedanib, Ofev, pirfenidone) require prior authorization: HRCT confirming diagnosis is required for all indications; dosing must follow FDA labeling; initial and reauthorization durations specified (commonly 1 year initial, 2 years reauth); reauthorization requires documentation of improvement or stability.

    • HRCT confirming diagnosis required
    • Follow FDA dosing
    • Initial typically 1 year; reauth commonly 2 years
    • Reauthorization: documentation of improvement or stability
    Prior Authorization

    Oxervate prior authorization

    Oxervate prior authorization requires documentation confirming Stage 2 or 3 neurotrophic keratitis (e.g., slit lamp exam), prescriber must be or consult an ophthalmologist, dosing per FDA labeling, and total lifetime treatment is limited to 8 weeks.

    • Confirm Stage 2 or 3 neurotrophic keratitis with exam
    • Prescribed by or in consultation with an ophthalmologist
    • Dosing per FDA label
    • Lifetime limit: 8 weeks
    Prior Authorization

    Promacta (eltrombopag) PA criteria

    Promacta (eltrombopag) PA for ITP initial requests requires a platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors, inadequate response/intolerance to steroids/IVIG and to rituximab or splenectomy; reauthorization requires current platelet <400 x10^9/L and documentation of response.

    • Platelets <30,000/mcL OR <50,000/mcL with bleeding/risk
    • Inadequate response/intolerance to steroids/IVIG AND rituximab or splenectomy
    • Reauthorization: current platelet <400 x10^9/L and evidence of response
    • Not covered to normalize platelet counts
    Prior Authorization

    Biologics: prior therapy & specialist requirement

    Many biologic/targeted immunomodulators require prior authorization documenting prior therapy trials and results and must be prescribed by or in consultation with a specialist; for psoriasis specifically, try and fail a traditional non‑biologic immunomodulator before biologic initiation.

    • Document prior therapies and responses
    • Prescriber specialist or consultation required
    • Psoriasis: try and fail one traditional non‑biologic immunomodulator (e.g., methotrexate)
    Prior Authorization

    Prior authorization and prescriber requirements

    Prior authorization generally requires documentation of prior therapies and responses; many products also require specialist prescribers or specialist consultation as part of the approval process.

    • Submit documentation of prior trials, intolerances, or contraindications
    • Confirm prescriber is a specialist or includes specialist consultation when required
    Prior Authorization

    Tolvaptan prior auth dosing limits

    Tolvaptan prior authorization requires documentation confirming hyponatremia type (hypervolemic or euvolemic) with serum sodium <125 mEq/L or symptomatic nonresponsive hyponatremia; dosing limits follow FDA labeling (up to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD).

    • Document hyponatremia type and serum sodium <125 mEq/L for hyponatremia use
    • Dose limits: up to 60 mg/day (hyponatremia) or up to 120 mg/day (ADPKD)
    • Coverage durations differ by indication (e.g., 30 days hyponatremia; 2 years ADPKD)
    Prior Authorization

    Prior authorization required

    Prior authorization is required for numerous products in this policy; providers must provide the specific prior‑therapy and diagnostic documentation indicated in each product entry.

    • Follow product‑specific documentation and prior therapy instructions
    • Use the alphabetical index to locate the product entry and requirements
    Prior Authorization

    Vowst: prior authorization & limits

    Vowst prior authorization: initial coverage limited to one treatment course (12 capsules over 3 days) for patients ≥18 with at least two recurrent CDI episodes (three or more total) after failure of appropriate antibiotics; coverage limited to a single course.

    • Document ≥2 recurrent CDI episodes (≥3 total) after failed appropriate antibiotics
    • Patient age ≥18
    • Limit: one treatment course (12 capsules over 3 days)
    Prior Authorization

    Xolair prior authorization

    Xolair requires prior authorization with submission of required diagnostic tests and clinical history: baseline IgE, current weight, and indication‑specific documentation (e.g., skin or in vitro reactivity for asthma or food allergy); intranasal steroid continuation required for nasal polyps and H1 antihistamine trial required for chronic urticaria.

    • Baseline IgE ≥30 IU/mL for relevant indications
    • Provide baseline positive skin or in vitro reactivity for asthma and food allergy
    • Provide current weight and age (food allergy ≥1 year)
    • Document trial/failure of ICS/LABA (asthma), intranasal steroid (nasal polyps), or H1 antihistamine (chronic urticaria)
    Note

    Prior authorization references

    This section indexes covered drugs and page references; specific prior authorization requirements are presented in the individual product entries rather than this index portion.

    Step Therapy

    Biologic prerequisite therapy

    For many biologic/immunomodulator indications (RA, psoriasis, AS, JIA, etc.), providers must document a trial and failure of a conventional non‑biologic immunomodulator or other condition‑specific first‑line therapy prior to biologic initiation.

    • Examples: methotrexate for RA/psoriasis, NSAID for ankylosing spondylitis
    • Failure defined as intolerance or inability to improve symptoms
    Step Therapy

    Auvelity step therapy

    Auvelity requires prior trial and failure of an SSRI or SNRI and one atypical antidepressant (e.g., bupropion or mirtazapine) prior to approval; failure is defined as inability to improve depressive symptoms after at least 4 weeks of treatment.

    • Trial/failure of SSRI or SNRI AND one atypical antidepressant
    • Failure = lack of improvement after ≥4 weeks
    Step Therapy

    Avmapki Fakzynja step therapy

    Avmapki Fakzynja Co‑Pack requires step‑therapy prerequisites per its product entry; providers must document prior therapy trials as specified.

    • Step therapy = yes; document prior therapies and responses
    Step Therapy

    Various step therapy requirements

    Multiple products require step therapy: providers must document trials and failures of specified generic or alternative therapies (examples include Balversa, calcipotriene‑betamethasone combinations, clobazam, Cosentyx) before the requested product will be approved.

    • Document each required prior trial and inadequate response or intolerance
    • Follow product‑specific durations and definitions of failure
    Step Therapy

    Eltrombopag step requirements

    Eltrombopag (Promacta) for ITP requires prior failure or intolerance to steroids/IVIG and to rituximab or splenectomy before approval; eltrombopag must not be used with other maintenance ITP drugs including other TPO‑RAs.

    • Prior failure/intolerance to steroids or IVIG
    • Prior failure/intolerance to rituximab or splenectomy
    • Do not use in combination with other maintenance ITP drugs
    Step Therapy

    Exxua step therapy

    Exxua (for MDD) requires trial and failure of two generic antidepressants from different classes, one of which must be bupropion or mirtazapine, documented prior to approval.

    • Two antidepressant trials from different classes required
    • One trial must be bupropion or mirtazapine
    Step Therapy

    Fanapt step therapy

    Fanapt requires documentation of trial and failure with two listed generic antipsychotics, each used for at least 28 days, before approval.

    • Two generic antipsychotic trials required (each ≥28 days)
    • Document inadequate response or intolerance
    Step Therapy

    Conventional therapy step requirements

    Many immunomodulator/biologic approvals require prior failure of one traditional non‑biologic immunomodulator or NSAID depending on indication (e.g., RA, AS, psoriasis, HS, uveitis); providers must document these trials and outcomes.

    • Document trial/failure of specified conventional therapy per indication
    • Failure defined as intolerance or inability to improve
    Step Therapy

    Inrebic step therapy

    Inrebic requires documentation of trial and failure of Jakafi (ruxolitinib) prior to approval; failure is defined as intolerance or inability to improve the condition.

    • Document prior Jakafi trial and inadequate response or intolerance
    Step Therapy

    Inrebic step

    Inrebic coverage requires prior Jakafi trial and failure (intolerance or inability to improve) documented in the request.

    Step Therapy

    Kerendia step/requirements

    Kerendia initial therapy for CKD with T2DM requires trial of an SGLT2 inhibitor or GLP‑1 RA and that the patient be on a maximally tolerated ACEI or ARB; for certain HF indications, Kerendia must be prescribed by or in consultation with a cardiologist and the patient be on standard HF meds.

    • Trial of SGLT2i or GLP‑1 RA required for CKD/T2DM
    • On maximally tolerated ACEI/ARB
    • Cardiologist prescribing/consult required for HF indication
    Step Therapy

    Lybalvi step therapy

    Lybalvi requires prior trial and failure of olanzapine and another generic atypical antipsychotic (e.g., aripiprazole or lurasidone) with failure defined as clinically significant weight gain (≥7%) despite clinical response.

    • Trial of olanzapine and another generic atypical antipsychotic required
    • Failure defined as clinical response with ≥7% weight gain
    Step Therapy

    Livtencity step

    Livtencity requires prior trial and failure of other CMV antivirals (ganciclovir, valganciclovir, cidofovir or foscarnet) and submission of a baseline CMV DNA level confirming diagnosis before approval.

    • Document baseline CMV DNA level
    • Document trial and failure of ganciclovir/valganciclovir/cidofovir/foscarnet
    Step Therapy

    Jylamvo prerequisite

    Jylamvo requires documentation supporting inability to use generic methotrexate prior to approval.

    • Provide rationale and records demonstrating inability to use generic methotrexate
    Step Therapy

    Levetiracetam step

    Levetiracetam oral disintegrating/soluble formulation requires documentation of inability to use generic levetiracetam tablet and trial/failure with one other generic anticonvulsant prior to approval.

    • Document inability to use generic levetiracetam tablet
    • Document trial and failure with one other generic anticonvulsant
    Step Therapy

    Mekinist formulation requirement

    Mekinist oral solution coverage requires documentation the patient is unable to swallow the tablet formulation.

    • Provide clinical documentation of inability to swallow tablets
    Step Therapy

    Mektovi biomarker requirement

    Mektovi requires documentation of BRAF V600 mutation status prior to approval.

    • Submit BRAF V600 mutation test results
    Step Therapy

    Nexletol/Nexlizet required prior therapy

    Nexletol/Nexlizet require prior trial of a high‑intensity statin plus ezetimibe (or statin intolerance with trial of two statins) with documentation of LDL‑C thresholds; providers must submit recent LDL‑C and prior therapy documentation.

    • Trial high‑intensity statin + ezetimibe ≥4 weeks OR ezetimibe ≥4 weeks if statin‑intolerant
    • Statin intolerance = tried ≥2 statins with symptoms on both
    • Submit most recent LDL‑C
    Step Therapy

    Nexlizet step therapy

    Nexlizet step therapy: patient must have tried one high‑intensity statin plus ezetimibe for at least 4 weeks (or maximally tolerated statin plus ezetimibe) with LDL‑C ≥70 mg/dL, or ezetimibe for 4 weeks with LDL‑C ≥70 mg/dL if statin‑intolerant; document LDL‑C and prior therapies.

    • Trial duration ≥4 weeks
    • LDL‑C threshold: ≥70 mg/dL
    • Document prior therapy and LDL‑C
    Step Therapy

    Otezla step therapy

    Otezla for moderate‑to‑severe psoriasis requires trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before approval; document prior therapies and responses.

    • Trial and failure of one traditional non‑biologic immunomodulator required
    • Step not required for mild psoriasis
    Step Therapy

    Allergic ophthalmic agents step requirement

    For allergic ophthalmic agents (Zaditor class), non‑preferred coverage requires trial and failure of a preferred product (azelastine or OTC ketotifen) for one month unless contraindicated.

    • Trial of preferred agent for one month required prior to non‑preferred
    Step Therapy

    Relistor: lactulose trial required

    Relistor requires a trial and failure of lactulose prior to coverage and exclusion if the patient has mechanical gastrointestinal obstruction.

    • Trial and failure of lactulose required
    • Do not approve if mechanical GI obstruction present
    Step Therapy

    Sodium oxybate: step therapy

    Sodium oxybate requires prior trials with stimulant and wake‑promoting agents (amphetamine/dextroamphetamine/methylphenidate AND modafinil or armodafinil) before approval for narcolepsy, plus diagnostic confirmation with polysomnography and MSLT and prescriber specialty.

    • Trial/failure of stimulant (amphetamine/dextroamphetamine/methylphenidate) AND modafinil or armodafinil
    • Provide MSLT and polysomnography confirming narcolepsy
    • Prescriber: sleep specialist or neurologist
    Step Therapy

    Psoriasis step requirement

    For psoriasis indications across biologic products, providers must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before some biologics will be approved.

    • Document prior trial and inadequate response to specified conventional agent
    Step Therapy

    Tyenne step requirement

    Tyenne (for RA and JIA) requires trials and failure of two specified agents (a preferred adalimumab product, Rinvoq, Xeljanz/XR, or Enbrel) prior to approval; document prior therapies and responses.

    • Trial and failure of two specified agents required
    • Document prior therapies and responses
    Step Therapy

    Narcolepsy step requirement

    Sodium oxybate for narcolepsy requires prior trial and failure of stimulant therapy (amphetamine salts/dextroamphetamine/methylphenidate) AND either modafinil or armodafinil before approval; provide diagnostic polysomnography/MSLT documentation.

    • Document stimulant + modafinil/armodafinil trial and failure
    • Submit MSLT and polysomnography confirming narcolepsy
    Step Therapy

    Step therapy requirements

    Many agents require documented prior trial and failure of specified conventional therapies (e.g., methotrexate for psoriasis/RA; NSAID for ankylosing spondylitis); providers must submit records demonstrating these trials and outcomes.

    • Provide dates, doses, durations, and reason for discontinuation/intolerance or inadequate response
    Step Therapy

    Xolair step therapy requirements

    Xolair step therapy: for chronic urticaria, document trial and failure of at least one H1 antihistamine prior to Xolair; for nasal polyps, document trial and failure of an intranasal steroid (and intranasal steroid must be continued with Xolair).

    • Chronic urticaria: trial/failure of one H1 antihistamine
    • Nasal polyps: trial/failure of intranasal steroid and continuation required
    Note

    index chunk — no step therapy rules

    This index portion contains drug names and page references only; step therapy rules are detailed in each individual product entry rather than the index chunks.

    Documentation Required

    General documentation

    Supporting documentation is required for all prior drug trials to demonstrate inadequate response, intolerance, or FDA‑labeled contraindication; providers must submit clinical notes, dates, doses, and objective measures where applicable.

    • Document trial dates, durations, doses, and clinical outcome
    • Include laboratory, imaging, or functional testing as required by product-specific criteria
    Documentation Required

    Adempas diagnostic documentation

    Adempas (riociguat) prior authorization requires diagnostic documentation: for PAH provide right heart catheterization confirming WHO Group 1; for CTEPH document inoperable disease or persistent/recurrent disease after pulmonary endarterectomy.

    • Submit right heart catheterization confirming PAH (WHO Group 1) for PAH indication
    • For CTEPH, document inoperability or persistent/recurrent disease after endarterectomy
    Documentation Required

    Arikayce microbiology documentation

    Arikayce prior authorization requires sputum culture supporting MAC diagnosis and documentation of failure to obtain negative sputum cultures after ≥6 months of multidrug background regimen; reauthorization requires a negative sputum culture within 30 days and prescriber specialty involvement.

    • Submit sputum culture demonstrating MAC infection
    • Document ≥6 months multidrug background regimen without negative cultures
    • Reauth: negative sputum culture within 30 days
    Documentation Required

    Amvuttra reauthorization

    Amvuttra reauthorization requires documentation demonstrating a positive clinical response compared to baseline (e.g., improved neuropathy symptoms, motor function, quality of life, or reduced cardiovascular events for ATTR‑CM).

    • Provide objective measures of clinical benefit versus baseline for reauthorization
    Documentation Required

    Prior therapy documentation

    Avmapki Fakzynja Co‑Pack initial requests require documentation of prior therapies and responses to treatment to support the prior authorization.

    • Submit prior therapy history and response details
    Documentation Required

    Benlysta diagnostic documentation

    Benlysta diagnostic documentation: for SLE initial requests submit SELENA‑SLEDAI ≥6 and serologic criteria (anti‑dsDNA >30 IU/mL or ANA >1:80) and proof of concomitant baseline therapy; for lupus nephritis submit kidney biopsy confirming class 3, 4 and/or 5 and documentation of standard LN therapy.

    • SLE: SELENA‑SLEDAI ≥6 AND anti‑dsDNA >30 IU/mL OR ANA >1:80
    • LN: kidney biopsy confirming class 3, 4, and/or 5
    • Document concomitant baseline agents and prior therapy
    Documentation Required

    Colistimethate microbiology documentation

    Colistimethate prior authorization requires culture and susceptibility information or local epidemiology/susceptibility patterns to support IV/IM use (nebulized/inhalation not covered); prescriber should be or consult an infectious disease specialist.

    • Provide culture and susceptibility or local epidemiology data
    • IV/IM administration only; nebulization not covered
    • Prescriber: infectious disease specialist or consult
    Documentation Required

    Asthma documentation

    For asthma biologic initial coverage, document oral corticosteroid dependence OR eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation or ≥300 cells/µL in past 12 months) AND trial/failure of one ICS/LABA in past 6 months; reauthorization requires documentation of clinical benefit compared to baseline.

    • Eosinophils: ≥150 cells/µL at initiation OR ≥300 cells/µL in prior 12 months
    • Document trial and failure of 1 ICS/LABA in past 6 months
    • Reauth: show clinical benefit vs baseline
    Documentation Required

    Hepatitis C documentation

    Epclusa (sofosbuvir/velpatasvir) requests require documentation of chronic hepatitis C infection and that use is consistent with current AASLD/IDSA guidance; pellets have age limits (3–21 years for pellets).

    • Provide documentation of chronic HCV infection
    • Ensure use aligns with AASLD/IDSA guidance
    • Pellets: age 3–21 years
    Documentation Required

    Evrysdi documentation

    Evrysdi requires submission of genetic testing confirming SMA diagnosis and prescriber neurologist involvement; reauthorization requires documentation demonstrating positive clinical response compared to baseline.

    • Submit genetic test confirming SMA
    • Prescriber: neurologist or consult
    • Reauth: documentation of positive clinical response vs baseline
    Documentation Required

    Prior therapy documentation

    Products such as Exxua require documentation of prior therapies and responses to support approval; include dates, doses, durations, and reason for discontinuation.

    • Provide prior therapy history with outcomes and dates
    Documentation Required

    Fasenra lab and benefit documentation

    Fasenra requires blood eosinophil counts within the specified windows and documentation of a trial/failure of an ICS/LABA; reauthorization requires documentation of clinical benefit compared to baseline.

    • Submit eosinophil counts per timeframe (≥150 within 6 weeks or ≥300 within 12 months)
    • Document trial/failure of ICS/LABA
    • Reauth: demonstrate clinical benefit
    Documentation Required

    Growth hormone documentation

    Growth hormone products require extensive testing documentation (growth velocity curves, GH‑stimulation tests, IGF‑1/IGFBP‑3 levels), open growth plates for children, and specialist prescribing (endocrinologist); provide reauthorization attestations as specified.

    • Submit growth velocity data and GH stimulation testing per pediatric/adult criteria
    • Prescriber must be endocrinologist/gastroenterologist/nephrologist
    Documentation Required

    HAE documentation

    Hereditary angioedema therapies (Haegarda, icatibant) require submission of C4, C1‑INH protein, and C1‑INH function lab results confirming diagnosis; Haegarda is not covered concurrently with ACE inhibitors or other preventative HAE therapies and reauthorization requires decreased attack frequency.

    • Submit C4, C1‑INH protein, and C1‑INH function tests
    • Do not use Haegarda with ACE inhibitors or other preventative HAE therapies
    • Reauth: document decreased frequency of attacks
    Documentation Required

    Shortened-interval dosing documentation

    For shortened‑interval dosing approvals with biologics in Crohn’s/UC, providers must submit at least two among symptoms, imaging showing active disease, fecal calprotectin >120, or CRP ≥300, plus inadequate trough levels and initial response to therapy.

    • Provide two of: symptoms, imaging of active disease, fecal calprotectin >120, CRP ≥300
    • Include drug trough levels and evidence of initial response
    Documentation Required

    IVIG documentation

    IVIG requests must include current weight and requested dose, documentation supporting the diagnosis and dose, and administration information to determine Medicare Part B versus Part D benefit when applicable.

    • Provide current weight and requested dose
    • Include diagnosis support and treatment records
    • Specify administration setting for benefit determination
    Documentation Required

    Livtencity documentation

    Livtencity requires baseline CMV DNA level confirming diagnosis and medical records showing trial and failure with ganciclovir/valganciclovir/cidofovir/foscarnet; reauthorization requires documentation of response (e.g., CMV DNA level).

    • Submit baseline CMV DNA
    • Document prior CMV antiviral trials and failures
    • Reauth: provide objective response measures
    Documentation Required

    LDL-C documentation

    For Nexletol/Nexlizet prior authorization, submit the most recent LDL‑C and documentation of prior therapies and responses to support approval per the LDL‑C thresholds.

    • Provide most recent LDL‑C
    • Include prior statin/ezetimibe therapy documentation and outcomes
    Documentation Required

    Kalydeco genetic testing

    Kalydeco requires laboratory confirmation of an ivacaftor‑responsive CFTR mutation (genetic testing) prior to approval.

    • Submit genetic test confirming ivacaftor‑responsive CFTR mutation
    Documentation Required

    Nexlizet — required labs and prior therapy documentation

    Nexlizet prior authorization and documentation must include the most recent LDL‑C and prior therapy records (statin/ezetimibe trials) to demonstrate eligibility under the LDL‑C threshold and step‑therapy rules.

    • Submit LDL‑C result and prior therapy history
    • Confirm statin + ezetimibe trial duration and outcomes
    Documentation Required

    HRCT and diagnostic documentation — nintedanib / Ofev

    For nintedanib and Ofev, HRCT confirming the diagnosis is required for all indications; for IPF rule out other causes and document UIP pattern if no biopsy; for progressive fibrosing ILD provide FVC decline data per criteria.

    • Submit HRCT confirming diagnosis (include HRCT report/images)
    • For IPF: document UIP pattern or surgical biopsy if applicable
    • For progressive phenotype: provide FVC decline data (≥10% or ≥5% plus worsening symptoms/imaging)
    Documentation Required

    Nulibry — genetic testing confirmation

    Nulibry prior authorization requires confirmed MoCD Type A diagnosis by genetic testing with submission of genetic test results.

    • Provide genetic test results confirming MoCD Type A
    Documentation Required

    Nuedexta — diagnostic medical records

    Nuedexta requests must include medical records supporting the diagnosis of pseudobulbar affect caused by an underlying neurologic condition; prescriber should be a neurologist.

    • Submit medical records documenting underlying neurologic condition and PBA diagnosis
    • Prescriber: neurologist
    Documentation Required

    PAH agents — right heart catheterization confirmation

    PAH agents (Opsumit, Opsynvi, Orenitram) require documentation that pulmonary arterial hypertension (WHO Group 1) is confirmed by right heart catheterization prior to approval.

    • Provide right heart catheterization report confirming WHO Group 1 PAH
    Documentation Required

    Pulmonary function and AAT levels

    Prolastin‑C prior authorization requires HRCT confirmation for some indications and documentation of pulmonary function (FEV1) and serum AAT level per specified thresholds (serum AAT <11 micromoles/L or equivalent).

    • Provide HRCT where required
    • Submit FEV1 and serum AAT level results
    Documentation Required

    Radicava: diagnostic and functional metrics

    Radicava initial prior authorization requires ALS diagnosis per revised El Escorial criteria, diagnosis ≤2 years, baseline ALSFRS‑R total ≥24 (≥2 points on each item), and %FVC ≥80%; reauthorization requires documentation that Radicava is slowing progression versus baseline.

    • Provide El Escorial/Arlie House diagnostic documentation and date of diagnosis (≤2 years)
    • Baseline ALSFRS‑R with minimum total 24; %FVC ≥80%
    • Reauth: evidence of slowed progression or stable/improved ALSFRS‑R
    Documentation Required

    Sodium oxybate: sleep study and prior trials

    Sodium oxybate prior authorization requires MSLT and polysomnography confirming narcolepsy and documentation of prior trials of stimulant and wake‑promoting agents; prescriber must be a sleep specialist or neurologist.

    • Submit polysomnography and MSLT confirming narcolepsy
    • Document prior stimulant and modafinil/armodafinil trials and outcomes
    • Prescriber: sleep specialist or neurologist
    Documentation Required

    Prior therapy documentation

    Providers must supply documentation of prior therapies and responses for multiple products across the policy to meet prior authorization requirements; absence of this documentation may lead to denial.

    • Include dates, doses, durations, outcomes, and rationale for stopping prior therapies
    Documentation Required

    Narcolepsy diagnostic documentation

    Narcolepsy diagnostic documentation: sodium oxybate requests must include MSLT and polysomnography confirming the diagnosis before approval.

    • Submit polysomnography and MSLT reports
    Documentation Required

    Tavneos documentation

    Tavneos prior authorization requires documentation to support the diagnosis, that the agent is used as an add‑on to standard therapy (cyclophosphamide, rituximab, steroids), and for reauthorization provide BVAS reduction and steroid dose documentation.

    • Provide diagnostic documentation and confirm add‑on use with standard therapy
    • Reauth: submit BVAS reduction and steroid dose information
    Documentation Required

    Osteoporosis prior therapy documentation

    Teriparatide/Tymlos prior authorization for osteoporosis requires documentation of prior bisphosphonate use or demonstration of very high fracture risk per T‑score or fracture history, and specialist prescribing.

    • Document prior bisphosphonate trial or T‑score ≤‑3.0 (or ≤‑2.5 with fragility fracture)
    • Prescriber: endocrinologist (as specified)
    Documentation Required

    Prior therapy and diagnostic documentation

    For certain heart‑failure or cardiology products, prior therapy and diagnostic documentation must include prior medications, response, and recent assessments (e.g., EF <45% measured within prior 12 months) to support approval.

    • Provide recent EF and prior medication history per product requirements
    Documentation Required

    Voydeya initial documentation

    Voydeya initial prior authorization requires flow cytometry‑confirmed PNH diagnosis, active treatment with ravulizumab or eculizumab, and evidence of symptomatic extravascular hemolysis (fatigue/dyspnea plus Hgb <9.5 g/dL or ARC >120 x10^9/L); reauthorization requires documentation of improvement in EVH symptoms and hemoglobin.

    • Submit flow cytometry confirming PNH
    • Document active complement inhibitor therapy (ravulizumab/eculizumab)
    • Provide Hgb and ARC data and symptom documentation
    • Reauth: demonstrate improved EVH symptoms and hemoglobin/hemolysis markers
    Documentation Required

    Xolair baseline documentation

    Xolair baseline documentation for asthma requires baseline IgE ≥30 IU/mL, positive skin or in‑vitro reactivity to a perennial aeroallergen, current weight, and trial/failure of an ICS/LABA in the past 6 months; reauthorization requires documentation of clinical benefit and current weight.

    • Baseline IgE ≥30 IU/mL (pre‑IgE‑lowering therapy)
    • Positive skin or in‑vitro reactivity to perennial aeroallergen
    • Document current weight and ICS/LABA trial/failure
    • Reauth: show clinical benefit and current weight
    Documentation Required

    Xolair — required documentation

    For Xolair food allergy initial requests, submit positive in‑vitro IgE and positive skin prick testing to specified foods, clinical history of significant allergic reaction, baseline IgE ≥30 IU/mL, current weight, and patient age ≥1 year; reauthorization requires continued avoidance diet, current weight and baseline IgE, and documentation of clinical benefit.

    • Positive in‑vitro IgE AND positive skin prick to specified foods
    • Clinical history of significant allergic reaction
    • Baseline IgE ≥30 IU/mL; current weight; age ≥1 year
    • Reauth: document clinical benefit and provide current weight and baseline IgE
    Documentation Required

    Yorvipath — required documentation

    Yorvipath initial authorization for chronic hypoparathyroidism requires labs drawn together (PTH, calcium, magnesium, phosphate), provider attestation that condition is not adequately controlled on calcium and vitamin D, endocrinologist prescribing/consult, and reauthorization must document improved serum calcium.

    • Provide PTH, calcium, magnesium, phosphate drawn together
    • Provider attestation of inadequate control on calcium and vitamin D
    • Prescriber: endocrinologist or consult required
    • Reauth: document improved serum calcium
    Note
    Denial Risk

    Acthar exclusions and limits

    Acthar is not covered for acute gouty arthritis, severe psoriasis, and atopic dermatitis; quantity is limited to FDA‑supported dosage and reauthorization requires demonstrated clinical benefit.

    • Not covered for acute gouty arthritis, severe psoriasis, atopic dermatitis
    • Quantity limited to FDA‑supported dosage
    • Reauthorization requires demonstrated clinical benefit
    Denial Risk

    GLP-1 weight loss exclusions/attestations

    Weight‑loss GLP‑1 agents require prescriber attestations (no concurrent GLP‑1 use, optimization for eating disorders, ruling out metabolic causes, contraindications such as pregnancy/lactation or MTC/MEN2), and confirmation that therapy is part of an overall weight‑management plan; absence of required attestations or contraindications may trigger denial.

    • Prescriber attest single‑agent class use and absence of contraindications
    • Confirm diet/exercise plan and prior failure of other interventions
    • Attest optimized treatment for eating disorder if present
    Denial Risk

    Amvuttra initial coverage risks

    Amvuttra initial coverage carries denial risk if required diagnostic confirmation is missing (TTR mutation, baseline PND score ≤IIIb, clinical signs for HATTR‑PN) or ATTR‑CM imaging/diagnostic criteria are incomplete; reauthorization requires documentation of positive clinical response versus baseline.

    • Submit TTR mutation and baseline PND score for HATTR‑PN
    • For ATTR‑CM, provide tafamidis trial history, NYHA class, cardiac imaging and confirmatory testing
    • Reauth: document clinical benefit
    Denial Risk

    Colistimethate administration restriction

    Colistimethate administration via nebulization/inhalation is not covered; only IV or IM administration is allowed and requires microbiologic documentation of susceptible bacteria or local epidemiology—lack of microbiology support will risk denial.

    • Nebulized/inhalation administration not covered
    • Provide culture/susceptibility or local epidemiology to support IV/IM use
    Denial Risk

    Austedo combination exclusion

    Austedo must not be used in combination with tetrabenazine or Ingrezza; requests documenting prohibited combinations will be denied.

    • Do not combine Austedo with tetrabenazine or Ingrezza
    Denial Risk

    Cosentyx combination exclusion

    Cosentyx must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors; requests indicating combination therapy will be excluded.

    • Combination with other biologics, Otezla, or JAKis is not allowed
    Denial Risk

    Benlysta combination exclusion

    Benlysta must not be used concomitantly with another biologic drug or Lupkynis; documentation of prohibited combination use will trigger denial.

    • Do not use Benlysta with other biologic drugs or Lupkynis
    Denial Risk

    Dalfampridine safety and documentation

    Dalfampridine carries denial risk if the patient has a history of seizure or creatinine clearance ≤50 mL/min; baseline timed 25‑foot walk and ambulatory status must be documented.

    • No history of seizure
    • Creatinine clearance >50 mL/min
    • Provide baseline timed 25‑foot walk and ambulatory status
    Denial Risk

    Dihydroergotamine mesylate nasal denial risk

    Dihydroergotamine mesylate nasal prior authorization may be denied if documentation of trial and failure of one non‑oral triptan and Nurtec ODT is not provided.

    • Document trial/failure of one non‑oral triptan
    • Document trial/failure of Nurtec ODT
    Denial Risk

    Epclusa denial risk

    Epclusa requests may be denied if documentation confirming chronic hepatitis C infection and alignment with AASLD/IDSA guidance is not provided.

    • Provide documentation of chronic HCV infection and guideline‑consistent use
    Denial Risk

    Haegarda excluded combinations/uses

    Haegarda is not covered if used with an ACE inhibitor, other preventative HAE therapies (Orladeyo, Takhyzro), or for acute attacks; missing C4/C1‑INH lab documentation will also risk denial.

    • Do not use Haegarda with ACE inhibitors or other preventative HAE therapies
    • Submit C4, C1‑INH protein, and C1‑INH function labs to confirm diagnosis
    Denial Risk

    Fasenra excluded combinations

    Fasenra must not be used in combination with other biologic drugs; documentation indicating combination use will be excluded.

    • Combination with other biologics is not permitted
    Denial Risk

    Biologic combination exclusions

    Many biologic products (e.g., Humira/Hadlima) are subject to combination therapy exclusions — concurrent use with other biologics, Otezla, or JAK inhibitors is not allowed and will result in denial.

    • Confirm no concurrent biologic, Otezla, or JAK inhibitor therapy
    Denial Risk

    Icatibant excluded combination

    Icatibant acetate concurrent use with an ACE inhibitor is not covered; providers must confirm ACE inhibitor is not being used.

    • Do not approve if patient is on an ACE inhibitor
    Denial Risk

    IVIG for myasthenia gravis

    IVIG for chronic or routine use in stable myasthenia gravis is not covered; approval is limited to acute myasthenic crisis with decompensation and requests must include current weight, requested dose, and supporting medical records.

    • Chronic/routine IVIG for stable MG is not covered
    • Provide weight, requested dose, and medical records for acute indications
    Documentation Required

    IVIG dosing documentation

    IVIG requests risk denial if current weight, requested dose, dosing rationale, and supporting medical records are not provided; dosing must follow FDA labeling or accepted standards including weight adjustments for BMI ≥30 or actual weight ≥20% over ideal.

    • Include current weight and requested dosing details
    • Provide diagnosis support and dosing calculation (weight‑adjusted if applicable)
    Denial Risk

    Concurrency exclusion — Nexlizet

    Nexlizet will be denied if used concomitantly with PCSK9 inhibitors (e.g., Repatha) — concurrent use is an exclusion.

    • Do not approve if PCSK9 inhibitor therapy is concurrent
    Denial Risk

    Concurrency exclusion — Nurtec

    Nurtec must not be used in combination with other CGRP antagonist therapy; combination use is excluded and will lead to denial.

    • Ensure no concurrent CGRP antagonist therapy
    Denial Risk

    Lifetime duration limit — Oxervate

    Oxervate has a lifetime treatment limit of 8 weeks; requests exceeding this limit will be denied or considered not covered.

    • Lifetime total treatment limited to 8 weeks
    Denial Risk

    Diagnostic documentation required

    Requests may be denied if diagnostic documentation required by the product entry is missing (for example, FEV1 <80% predicted and low serum AAT for Prolastin‑C); providers must include all required diagnostic tests.

    • Include all required diagnostic tests (labs, imaging, functional studies) per product
    Denial Risk

    Prior therapy / prescriber requirements

    Denial risk exists when prior therapy requirements or specialist prescriber requirements are not documented; providers must include evidence of specified trials, failures/intolerances, and specialist involvement when required.

    • Document prior trials, durations, outcomes, and specialist consultations as required
    Denial Risk

    Combination therapy exclusions

    Combination therapy exclusions apply to many products; use in combination with other biologic drugs, Otezla, or JAK inhibitors where prohibited will be excluded from coverage.

    • Verify no prohibited combination therapies are present
    Denial Risk

    Sodium oxybate exclusions

    Sodium oxybate exclusions: patients receiving sedative hypnotics or with succinic semialdehyde dehydrogenase deficiency are excluded and such combinations or contraindications will preclude coverage.

    • Do not approve if sedative hypnotics are being taken concurrently
    • Do not approve if succinic semialdehyde dehydrogenase deficiency present
    Denial Risk

    Combination exclusion

    Voydeya is not covered in combination with Fabhalta or Empaveli; requests indicating prohibited combinations will be denied.

    • Do not combine Voydeya with Fabhalta or Empaveli
    Denial Risk

    Exclusion by diagnosis

    Vyndamax will be denied for patients with primary (light‑chain) amyloidosis; ensure diagnosis is transthyretin ATTR‑CM and not light‑chain amyloidosis.

    • Confirm ATTR‑CM diagnosis and exclude primary (light‑chain) amyloidosis
    Denial Risk

    Indication restrictions

    Xifaxan coverage limits: coverage for SIBO is not provided and IBS‑D is limited to no more than three 14‑day treatment courses; for travelers’ diarrhea and hepatic encephalopathy, document required prior trials (e.g., azithromycin or lactulose).

    • IBS‑D: up to three 14‑day courses
    • SIBO: coverage not provided
    • TD: document trial/failure of azithromycin; HE: trial/failure of lactulose
    Denial Risk

    Documentation-dependent denials

    Requests lacking documentation of required diagnostic testing, clinical history, baseline IgE, current weight, or failure/response documentation (as specified per indication) may be denied; providers must include all specified elements from the product entry.

    • Ensure all indication‑specific documentation (labs, tests, prior therapy history) is submitted
    Denial Risk

    Combination therapy exclusion

    Certain products are excluded from combination use with other biologic drugs, Otezla, or JAK inhibitors; document that the requested agent is not being used concurrently with excluded agents to avoid denial.

    • Verify no concurrent excluded biologics, Otezla, or JAKis
    Note

    This index section provides an alphabetical listing of covered drugs and page references; it does not itself state authorization or denial rules — refer to each drug’s criteria entry for actionable requirements.

    Policy Background

    This document provides the prior authorization criteria, clinical prerequisites, exclusions, documentation requirements, quantity and duration limits, step‑therapy rules, prescriber and site‑of‑care expectations, and reauthorization conditions used to adjudicate coverage for Priority Medicare Dual Premier (HMO D‑SNP) pharmacy and specialty drugs. An alphabetical index of covered drugs appears after the criterion listings and individual product sections [[chunk 1]][[chunk 180]].

    Coverage decisions described here are product‑specific and generally require one or more of the following before approval: prior trials and documented failures of specified therapies, specialist prescriber or consult, diagnostic confirmation (e.g., HRCT, right heart catheterization, genetic testing), baseline labs or functional measures, and attestation of contraindications or contraindicated combinations. Many biologics and targeted therapies require documentation of prior non‑biologic therapy and prohibit concurrent use with other biologic agents, Otezla, or JAK inhibitors [[chunk 4]][[chunk 3]][[chunk 126]].

    The policy sets typical initial and reauthorization durations (commonly 1–2 years depending on product), explicit quantity limits for selected products, and specific lifetime limits where applicable (for example, Oxervate limited to 8 weeks lifetime). Reauthorization nearly always requires documentation of clinical benefit compared with baseline (examples: improved ALSFRS‑R for Radicava, decreased migraine days for CGRP agents, improved labs or symptoms for many agents) [[chunk 2]][[chunk 113]][[chunk 96]][[chunk 104]].

    To avoid denials, providers should submit the required supporting documentation indicated for each product entry — e.g., most recent LDL‑C and prior statin/ezetimibe therapy for Nexlizet, sputum culture and prior multidrug regimen documentation for Arikayce, HRCT for antifibrotic agents, or baseline IgE and confirmatory testing for Xolair — and attest to any required contraindication checks or combination‑therapy exclusions noted in the product criteria [[chunk 30]][[chunk 92]][[chunk 82]][[chunk 161]].

    Definitions and Clinical Terms

    inv-248: Statin intolerance
    Statin intolerance definitionTried at least two different statins and experienced statin-related symptoms on both agents (defines statin intolerance for Nexlizet/Nexletol pathways)
    ImplicationAllows use of ezetimibe alone pathway when statin-intolerant for LDL-C criteria
    Documentation requiredPrior therapy documentation (trials, intolerances) must be submitted with LDL-C levels
    inv-249: HRCT confirmation
    HRCT confirmation requirementHigh-resolution CT (HRCT) confirming diagnosis required for nintedanib/Ofev and other antifibrotic indications
    Role in IPFFor IPF: HRCT must show UIP pattern if no surgical lung biopsy; other causes of ILD must be ruled out
    Prescriber requirementPrescriber must be or have consulted a pulmonologist/specialist
    inv-250: Baseline IgE
    Baseline IgE (definition)IgE measured before treatment with Xolair or another therapy that lowers IgE levels (baseline) is required and should be ≥30 IU/mL where specified
    Indication-specific useUsed to determine eligibility for Xolair in asthma, nasal polyps, and food allergy indications
    DocumentationBaseline IgE must be submitted with PA request and at reauthorization as required
    inv-251: Chronic hypoparathyroidism (coverage context)
    Chronic hypoparathyroidism definitionDefined as duration ≥6 months with lab confirmation (serum PTH, calcium, magnesium, phosphate drawn together)
    Prior therapy attestationProvider must attest that condition is not adequately controlled on calcium and vitamin D (e.g., calcitriol) alone
    Prescriber requirementPrescribed by or in consultation with an endocrinologist

    Initial Therapy Criteria (Selected Products)

    Reauthorization / Continuation Criteria

    Step Therapy Requirements

    ScenarioRequired prior therapy / stepNotes
    Biologic initial therapy prerequisite
    Trial and failure of a traditional non-biologic immunomodulator (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) — or condition-specific first-line therapy (NSAID for AS, other specified agents for HS/uveitis/JIA)
    Failure defined as intolerance or inability to improve symptoms; prescriber usually specialist; dosing per FDA labeling; applies across many biologic indications (RA, psoriasis, AS, HS, uveitis, JIA)
    DrugRequired prior trialsDuration / Notes
    Auvelity (dextromethorphan-bupropion)
    Trial and failure (≥4 weeks without adequate improvement) of an SSRI or SNRI AND one atypical antidepressant (e.g., bupropion or mirtazapine)
    Coverage duration two years; dosing must follow FDA labeling; documentation of prior therapies and responses required
    DrugRequired prior trials for MDDNotes
    Caplyta (lurasidone) / related antidepressant prior trials (example)
    For MDD adjunctive or bipolar depressive indications: trial and failure of two generic antidepressants from different classes; one must be bupropion or mirtazapine (per class examples) — documentation required
    Patient must be ≥18 where specified; coverage duration commonly two years; prior therapies and responses must be provided
    IndicationRequired prior therapy / stepNotes
    Cosentyx — Psoriasis
    Must try and fail one traditional non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin)
    Prescriber specialist or consult required; coverage duration two years; must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors
    ScenarioRequired prior therapyDocumentation
    Duloxetine / other antidepressant prerequisite example
    Must document inability to use duloxetine (generic) AND trial and failure with one other generic antidepressant (failure = inability to improve)
    Current documentation supporting inability to use duloxetine and prior trial/failure required; coverage typically two years
    IndicationRequired prior trialsNotes
    Eltrombopag (Promacta) — ITP initial
    Inadequate response or intolerance to steroids or IVIG AND inadequate response or intolerance to rituximab or splenectomy prior to eltrombopag
    Platelet count thresholds apply (<30,000/mcL or <50,000/mcL with bleeding or bleeding risk); not to be used in combination with other maintenance ITP drugs; reauthorization requires platelet <400 x10^9/L and evidence of response
    DrugRequired prior trialsNotes
    Exxua (MDD)
    Trial and failure of two generic antidepressants from different classes; one must be bupropion or mirtazapine
    Documentation of prior therapies and responses required; coverage duration two years
    DrugRequired prior trialsDuration / Notes
    Fanapt (iloperidone)
    Trial and failure with two listed generic antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, lurasidone), each used ≥28 days
    Documentation that each comparator was used ≥28 days and inadequate response required; coverage two years
    Condition / ClassRequired conventional therapy stepNotes
    Immunologic / rheumatologic diseases (e.g., RA, psoriasis, AS, HS, uveitis, JIA)
    Must try and fail one traditional non-biologic immunomodulator (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) or one NSAID where indicated
    Failure defined as intolerance or inability to improve; prescriber specialist or consultation commonly required; combination with other biologics/JAKis or Otezla often prohibited
    RequirementPrior agentNotes
    Specified prior agent trial requirement (example)
    Must have tried and failed Jakafi (ruxolitinib) prior to coverage of Inrebic
    Failure defined as intolerance or inability to improve the condition; documentation required; coverage typically two years
    DrugRequired prior trialsNotes
    Lybalvi (olanzapine/samidorphan)
    Must have tried and failed olanzapine AND another generic atypical antipsychotic (e.g., aripiprazole or lurasidone) with failure defined as clinically significant weight gain (≥7%) despite clinical response
    Not covered for patients currently using opioids or undergoing acute opioid withdrawal; documentation of diagnosis, baseline and current weight required; coverage one year
    DrugRequired prior agentsNotes
    Livtencity (letermovir) antiviral prior trials
    Trial and failure with ganciclovir, valganciclovir, cidofovir, or foscarnet required prior to approval
    Baseline CMV DNA level confirming diagnosis required; must not be used concomitantly with other CMV antivirals; reauthorization requires documentation of response; dosing per FDA labeling
    DrugRequired prior therapyDuration / Notes
    Nexletol / Nexlizet (bempedoic acid +/- ezetimibe)
    Trial of a high-intensity statin plus ezetimibe for ≥4 weeks (or maximally tolerated statin plus ezetimibe) OR ezetimibe alone ≥4 weeks if statin-intolerant (statin intolerance = tried ≥2 statins with symptoms)
    Submit most recent LDL-C; LDL-C threshold ≥70 mg/dL; must not be used with PCSK9 inhibitors or Juxtapid; coverage two years
    TopicRequirementNotes
    Nexlizet trial duration and alternatives
    High-intensity statin + ezetimibe for at least 4 weeks, or ezetimibe alone for 4 weeks if statin-intolerant; statin intolerance defined as trying ≥2 statins with statin-related symptoms on both
    LDL-C must remain ≥70 mg/dL after prior therapy; documentation of prior therapies and LDL-C required; concurrent PCSK9 inhibitors not allowed
    IndicationRequired prior therapyNotes
    Otezla — moderate to severe psoriasis
    Try and fail one traditional non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before Otezla; step not required for mild psoriasis
    Documentation of prior therapies and responses required; dosing per FDA label; coverage two years
    RequirementPrior agentNotes
    Semaglutide prerequisite example
    Must try and fail semaglutide prior to approval where specified (example: Rezdiffra entry requires semaglutide trial)
    Documentation supporting trial and failure required; prescriber specialist as specified; coverage and dosing per product-specific rules
    RequirementRequired trialsNotes
    Two-generic-drug trial requirement (example)
    Must have documentation of trial and failure with two listed generic drugs used at least 28 days each (e.g., aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, lurasidone)
    Failure defined as inadequate response; documentation required for approval; coverage typically two years
    ScenarioPrior therapy requiredNotes
    Psoriasis prior therapy before biologic (class example)
    Must try and fail one traditional non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before many biologics (e.g., Cosentyx, ustekinumab, others)
    Prescriber specialist or consult required; documentation of prior therapies and responses required; combination with other biologics/JAKis/Otezla prohibited
    DrugRequired prior trialsNotes
    Tyenne (class example) — RA/JIA
    Trial and failure of two of the following: a preferred adalimumab product, Rinvoq, Xeljanz/XR, or Enbrel
    Documentation required; prescriber specialist; coverage duration two years; must not be used with other biologic drugs, Otezla, JAKis, or Ofev where specified
    General ruleTypical prior trial / failureExamples / Notes
    General prior trial / failure requirements
    Many agents require prior trial/failure of specified traditional non-biologic immunomodulators or other standard therapies (e.g., methotrexate for psoriasis/RA; NSAID for ankylosing spondylitis; two generic anticonvulsants for refractory seizures)
    Documentation of trials, durations, and responses required; prescriber specialist often required; coverage durations commonly 1–2 years
    IndicationRequired prior therapyNotes
    Xolair — chronic urticaria
    Trial and failure of one H1 antihistamine prior to Xolair
    For nasal polyps: trial and failure of an intranasal steroid required and intranasal steroid must be continued with Xolair; documentation of baseline IgE and weight required; reauthorization requires clinical benefit

    Quantity Limits and Dosing Caps

    inv-294: Ojemda oral suspension
    Quantity limit (Ojemda oral suspension)Limited to 1 box per 28 days (oral suspension when patient unable to swallow tablet)
    Formulation requirementOral suspension coverage requires inability to swallow tablet formulation
    DurationInitial coverage typically 1 year with this limit
    inv-295: Prevymis Oral Tablet/Packet
    Quantity limit (Prevymis)Quantity limit: 200 (per documentation in policy; submit as specified)
    Coverage durationCoverage duration commonly two years unless otherwise specified
    DocumentationSupporting clinical documentation required with prior authorization requests
    inv-296: Radicava ORS
    Radicava ORS quantity limits70 mL for first 28 days then 50 mL every 28 days thereafter (initial volume limits)
    Initial diagnostic thresholdsALS diagnosis per revised El Escorial, diagnosis ≤2 years, baseline ALSFRS-R ≥24, %FVC ≥80%
    Reauthorization requirementDocumentation of slowed progression (stable or improved ALSFRS-R) required for reauth
    inv-297: Scemblix 20 mg
    Scemblix 20 mg quantity limitLimit: 60 tablets per 30 days
    Prescriber requirementMust be prescribed by or in consultation with an oncologist/hematologist for applicable indications
    Age restrictionMust be 18 years or older for listed indications
    inv-298: Scemblix 40 mg
    Scemblix 40 mg quantity limitLimit: 240 tablets per 30 days
    Prescriber requirementPrescribed by or in consultation with an oncologist/hematologist
    Indication-specific documentationMutation confirmation required for some indications (e.g., T315I) as noted
    inv-299: tolvaptan
    Tolvaptan daily dosing limitsUp to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD (per FDA labeling)
    Serum sodium requirementFor hyponatremia: serum sodium <125 mEq/L or symptomatic nonresponsive hyponatremia required
    Documentation requirementConfirm hyponatremia type (hypervolemic or euvolemic) and adherence to dosing limits in PA submission
    inv-300: Vowst
    Vowst treatment course limitLimited to 1 treatment course (12 capsules over 3 days)
    Indication requirementDocument at least 2 recurrent CDI episodes (3+ total) after failure of appropriate antibiotics; patient must be ≥18 years old
    Coverage durationInitial coverage typically 1 year with single-course limit
    inv-301: Xifaxan (IBS-D)
    Xifaxan IBS-D course limitUp to three 14-day treatment courses per indication (IBS-D)
    SIBO exclusionCoverage for small intestinal bacterial overgrowth (SIBO) is not provided
    Traveler's diarrhea limitTravelers' diarrhea (TD) limited to three days per episode with prior trial of azithromycin required

    Site of Care and Benefit Determination

    Note
    Note
    Note
    Note
    Note